In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Sign Up To Get Our Instant Alerts!
- Japanese Premier Declares COVID-19 State of Emergency in Tokyo 56 views
- 4CABLE TV INTERNATIONAL, INC. ANNOUNCES SETTLEMENT OF THE MARQUIS TRADING DEBT, OPENING OF THE FIRST OF ITS KIND HIP RESTAURANT AND THE UNDERGOING OF REPAIRS AT THE CIGN FARM 42 views
- Expect Even More Unique Electric Cars Says Ferrari 40 views
- U.S Resumes Talks With Embattled Huawei CFO Meng Wanzhou 30 views
- BT and Ericsson Partners to Build Private 5G Networks 28 views